Heparin Panpharma (Heparin Sodium)

Heparin Panpharma is indicated for several clinical situations where anticoagulation is required.

• Prevention and treatment of deep vein thrombosis (DVT) in the lower extremities.
• Prevention and treatment of pulmonary embolism (PE) following surgery or immobilization.
• Anticoagulation during cardiac surgery, cardiopulmonary bypass, and renal dialysis to maintain circuit patency.
• Management of acute coronary syndromes, including unstable angina and non‑ST elevation myocardial infarction, when rapid anticoagulation is required.
• Prophylaxis of clot formation in patients with high thrombotic risk, such as those with cancer or prolonged immobilization.

Heparin Panpharma may be associated with a range of adverse effects that vary in frequency and clinical significance.

Common

• Minor bleeding at injection site or from mucous membranes (e.g., nosebleeds, gum bleeding).
• Mild thrombocytopenia (decrease in platelet count) detectable on routine labs.
• Elevated liver enzymes indicating transient hepatic irritation.
• Localized bruising or hematoma at the subcutaneous injection site.
• Transient headache or dizziness.
• Mild nausea or vomiting occasionally reported.

Serious

• Major hemorrhage, including intracranial or gastrointestinal bleeding.
• Heparin‑induced thrombocytopenia (HIT) with paradoxical clot formation.
• Severe allergic reactions such as anaphylaxis.
• Spontaneous spinal or epidural hematoma leading to neurologic compromise.
• Acute adrenal insufficiency secondary to adrenal hemorrhage.

When prescribing Heparin Panpharma, clinicians should consider several precautions to minimize the risk of complications and ensure safe use.

• Assess baseline coagulation parameters (e.g., aPTT, platelet count) before initiating therapy.
• Adjust dose in patients with renal or hepatic impairment, as drug clearance may be altered.
• Use caution in individuals with a history of heparin‑induced thrombocytopenia or known hypersensitivity to heparin.
• Monitor for signs of bleeding, especially during invasive procedures or in the elderly.
• Avoid concurrent use with other anticoagulants or antiplatelet agents unless specifically indicated.
• Re‑evaluate anticoagulation needs regularly in patients undergoing surgery or prolonged immobilization.

Heparin Panpharma can interact with other medicines that affect hemostasis or drug metabolism, potentially altering its anticoagulant effect.

Avoid

• Concurrent use with other parenteral anticoagulants (e.g., direct thrombin inhibitors, low‑molecular‑weight heparins) due to additive bleeding risk.
• Combination with potent antiplatelet agents such as clopidogrel or ticagrelor without close monitoring.
• Co‑administration with fibrinolytic therapy (e.g., alteplase) because of synergistic hemorrhagic potential.

Use with caution

• NSAIDs, aspirin, or other non‑steroidal anti‑inflammatory drugs that may increase mucosal bleeding.
• Certain antibiotics (e.g., cefazolin) that can potentiate heparin activity.
• Drugs affecting platelet function such as SSRIs or selective serotonin reuptake inhibitors.
• Renal‑clearing medications that may require dose adjustment of heparin.